These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 20812163)

  • 1. ["The Lantus case": and yet it does move (or not?)].
    Schöffski O
    Dtsch Med Wochenschr; 2010 Sep; 135(36):1755-6. PubMed ID: 20812163
    [No Abstract]   [Full Text] [Related]  

  • 2. [My quality of life has increased with Lantus].
    Euler H
    Lakartidningen; 2004 Sep; 101(39):3015; discussion 3016. PubMed ID: 15493645
    [No Abstract]   [Full Text] [Related]  

  • 3. [Are the short-acting insulin analogs superfluous?].
    Arand M
    MMW Fortschr Med; 2006 Mar; 148(11):17. PubMed ID: 16612957
    [No Abstract]   [Full Text] [Related]  

  • 4. [Short acting insulin analogues for type 2 diabetes. Unnecessary additional expenditure or valuable added benefit? Interview by Böhm Sanja].
    Hess R; Kerner W
    Dtsch Med Wochenschr; 2006 Oct; Suppl 1():36-7. PubMed ID: 17595817
    [No Abstract]   [Full Text] [Related]  

  • 5. [Costs of antihyperglycemic drugs and consumables and treatment satisfaction in patients with type 2 diabetes. Results of the health care research study LIVE-DE (long-acting insulin glargine compared with NPH insulin in Germany)].
    Hauner H; Kohlmann T; Landgraf W; Holle R; Pirk O; Scholten T
    Dtsch Med Wochenschr; 2009 Jun; 134(23):1207-13. PubMed ID: 19472091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resource utilisation and costs in patients with type 2 diabetes mellitus treated with insulin glargine or conventional basal insulin under real-world conditions in Germany: LIVE-SPP study.
    Schöffski O; Breitscheidel L; Benter U; Dippel FW; Müller M; Volk M; Pfohl M
    J Med Econ; 2008; 11(4):695-712. PubMed ID: 19450076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ["The Lantus Case": What is the benefit of health economics?].
    Schöffski O
    Dtsch Med Wochenschr; 2010 May; 135(20):1033-5. PubMed ID: 20461663
    [No Abstract]   [Full Text] [Related]  

  • 8. Insulin glargine for type 2 diabetes.
    Hemraj F; Garces K
    Issues Emerg Health Technol; 2004 Aug; (59):1-4. PubMed ID: 15311441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Basal insulin in discussion--clinical and health economics aspects].
    Middeke M
    Dtsch Med Wochenschr; 2008 Aug; 133 Suppl 4():S99; discussion S124-6. PubMed ID: 18686223
    [No Abstract]   [Full Text] [Related]  

  • 10. [Costs of antihyperglycemic treatment and consumables and treatment satisfaction in patients with type 2 diabetes].
    Schröder J; Kerner W
    Dtsch Med Wochenschr; 2009 Nov; 134(46):2355; author reply 2355-6. PubMed ID: 19894207
    [No Abstract]   [Full Text] [Related]  

  • 11. [Current cost analysis in the management of diabetes mellitus].
    Oberender P
    Dtsch Med Wochenschr; 2008 Aug; 133 Suppl 4():S110-4; discussion S124-6. PubMed ID: 18686219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cost-effectiveness of insulin glargine vs. neutral protamine Hagedorn insulin in type 2 diabetes: a focus on health economics.
    Levin P
    Diabetes Obes Metab; 2008 Jul; 10 Suppl 2():66-75. PubMed ID: 18577158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prevention and early therapy play too minor a role in our health care system].
    Rothe HJ
    Med Klin (Munich); 2003 Oct; 98 Suppl 1():22-3. PubMed ID: 14694840
    [No Abstract]   [Full Text] [Related]  

  • 14. [Economics under scrutiny - experts discuss long acting insulin analogs].
    Pflege Z; 2011 Jan; 64(1):58. PubMed ID: 21305792
    [No Abstract]   [Full Text] [Related]  

  • 15. [The first inhalational insulin. Which patients really profit from it? (interview by Dr. D. Einecke)].
    Schumm-Draeger PM
    MMW Fortschr Med; 2007 Jan; 149(1-2):16-7. PubMed ID: 17632858
    [No Abstract]   [Full Text] [Related]  

  • 16. [Lantus is superior in BOT (basic oral therapy) to standard mixed insulin].
    Krankenpfl J; 2004; 42(5-6):172. PubMed ID: 15527234
    [No Abstract]   [Full Text] [Related]  

  • 17. Whither inhaled insulin?
    Young B
    Nat Clin Pract Endocrinol Metab; 2006 Aug; 2(8):413. PubMed ID: 16932324
    [No Abstract]   [Full Text] [Related]  

  • 18. Costs Associated With Using Different Insulin Preparations.
    Tylee T; Hirsch IB
    JAMA; 2015 Aug; 314(7):665-6. PubMed ID: 26284715
    [No Abstract]   [Full Text] [Related]  

  • 19. Insulin detemir (levemir), a new long-acting insulin.
    Med Lett Drugs Ther; 2006 Jul; 48(1238):54-5. PubMed ID: 16841022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China.
    Palmer JL; Gibbs M; Scheijbeler HW; Kotchie RW; Nielsen S; White J; Valentine WJ
    Adv Ther; 2008 Aug; 25(8):752-74. PubMed ID: 18704282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.